Real-world effectiveness of first-line immunotherapy with or without chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer - PubMed
2 hours ago
- #non-small cell lung cancer
- #immunotherapy
- #real-world evidence
- A real-world study compared first-line immunotherapy with/without chemotherapy to chemotherapy alone in advanced NSCLC, showing a significant improvement in median overall survival (22.0 vs. 14.0 months, p < 0.0001).
- No significant overall survival difference was found between domestically developed PD-1 inhibitors (e.g., camrelizumab) and the international agent pembrolizumab (median 22.0 vs. 24.0 months, p = 0.28), though results are limited by sample size.
- Concomitant corticosteroid use was linked to shorter overall survival (20.0 vs. 26.0 months, p = 0.036), while antibiotics and proton pump inhibitors showed non-significant trends toward reduced survival.
- Subgroup analyses suggested potential survival benefit heterogeneity based on factors like BMI and smoking status, but these findings require cautious interpretation due to limited subgroup sizes.